Follow the Data: Applying TILs PSI as a correlate to response in combination checkpoint therapy1

Research Area: Checkpoint & combination therapy

Development Stage: Prediction

Goal: Find correlates to in vivo patient response in combination checkpoint therapy (Ipi & Nivo)

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#29acd8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#29acd8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#9cc9d8" button_border_hover_color="#9cc9d8" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution: IsoPlexis' PSI successfully stratifies patient responders and non-responders

Finding: Polyfunctional strength uniquely correlated with response, while histology and serum cytokine measurements did not

Follow the data

Single cell polyfunctionality shows positive correlation with clinical anti-tumor responses after treatment. Samples from responders have 9x more polyfunctional cells than non-responders, and 40x higher polyfunctional strength (p= 0.0294).

Individual cells secreted various combinations of effector cytokines (Granzyme B, IFN-γ, MIP-1α, Perforin and TNF-α) associated with anti-tumor immunity.1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="https://isoplexis.com/wp-content/uploads/2019/02/IsoPlexis-AppHighlight-Bispecifics.pdf" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application highlight
to learn more >[/ce_button]

IsoPlexis finds critical differences

PSI as a biomarker outperformed other measured metrics. Single-Cell PSI of CD8+ TILs significantly correlates with outcome of anti-PD-1/CTLA4 treated patients with metastatic melanoma.

No significant association was identified between clinical outcome and other measurements, including TILs % by histopathological assessment or serum concentration.1